{"disease":{"id":"parkinson-disease","name":"parkinson disease"},"drugs":{"marketed":[{"drug_id":"pimavanserin","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuplazid","generic_name":"PIMAVANSERIN","company_name":"Acadia Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":70,"revenue":"600","mechanism":"Nuplazid works by blocking the action of a specific chemical messenger in the brain called serotonin."},{"drug_id":"bia-9-1067","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ongentys","generic_name":"BIA 9-1067","company_name":"Neurocrine Biosciences","drug_phase":"marketed","molecular_target":"Catechol O-methyltransferase","drug_class":"Catechol-O-Methyltransferase Inhibitor [EPC]","quality_score":59,"revenue":"200","mechanism":"Ongentys works by blocking the enzyme that breaks down dopamine, allowing more dopamine to be available in the brain."},{"drug_id":"cycrimine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pagitane","generic_name":"CYCRIMINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"levodopa","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inbrija","generic_name":"LEVODOPA","company_name":"Merz","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Fyn","drug_class":"Aromatic Amino Acid [EPC]","quality_score":10,"revenue":null,"mechanism":"Levodopa works by crossing the blood-brain barrier and being converted into dopamine, a neurotransmitter that helps regulate movement and coordination."},{"drug_id":"foscarbidopa","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FOSCARBIDOPA","company_name":"AbbVie GK","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":"Foscarbidopa works by increasing the levels of dopamine in the brain, a neurotransmitter that is often deficient in people with Parkinson's disease."},{"drug_id":"foslevodopa","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FOSLEVODOPA","company_name":"AbbVie GK","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":"Foslevodopa works by increasing the levels of levodopa in the brain, which helps to alleviate symptoms of Parkinson's disease."},{"drug_id":"carbidopa","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sinemet Cr","generic_name":"CARBIDOPA","company_name":"Aton","drug_phase":"marketed","molecular_target":"Lysine-specific demethylase 4E","drug_class":"Aromatic Amino Acid [EPC]","quality_score":54,"revenue":null,"mechanism":"Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, relieving Parkinson's disease symptoms."},{"drug_id":"selegiline","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Selegiline Hydrochloride","generic_name":"SELEGILINE","company_name":"Somerset","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B","drug_class":"Monoamine Oxidase Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"apomorphine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apokyn","generic_name":"APOMORPHINE","company_name":"Mdd Us","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"bromocriptine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parlodel","generic_name":"BROMOCRIPTINE","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Ergot Derivative","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"droxidopa","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Northera","generic_name":"DROXIDOPA","company_name":"Lundbeck Na Ltd","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Catecholamine","quality_score":63,"revenue":null,"mechanism":"Northera works by increasing the levels of certain neurotransmitters in the brain, such as norepinephrine, to help regulate blood pressure and movement."},{"drug_id":"trihexyphenidyl-hydrochloride","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"rotigotine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupro","generic_name":"ROTIGOTINE","company_name":"UCB","drug_phase":"marketed","molecular_target":"dopamine receptors","drug_class":"Nonergot Dopamine Agonist [EPC]","quality_score":65,"revenue":null,"mechanism":"Rotigotine stimulates dopamine receptors in the brain, which may help treat Parkinson's disease and Restless Legs Syndrome."},{"drug_id":"entacapone","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comtan","generic_name":"ENTACAPONE","company_name":"Orion Pharma","drug_phase":"marketed","molecular_target":"Catechol O-methyltransferase","drug_class":"Catechol-O-Methyltransferase Inhibitor [EPC]","quality_score":60,"revenue":null,"mechanism":"Comtan works by blocking the enzyme catechol-O-methyltransferase, which breaks down dopamine in the brain."},{"drug_id":"apokyn","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"APOKYN","company_name":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Dopaminergic Agonist","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"lodosyn","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lodosyn","company_name":"University of Miami","drug_phase":"discontinued","molecular_target":"Lysine-specific demethylase 4E, Aromatic-L-amino-acid decarboxylase, Tyrosine-protein kinase Fyn","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"exelon","indication_name":"Dementia associated with Parkinson's Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Exelon","company_name":"US Department of Veterans Affairs","drug_phase":"marketed","molecular_target":"Acetylcholinesterase, Cholinesterase, Acetylcholine receptor subunit epsilon","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"rivastigmine","indication_name":"Dementia associated with Parkinson's Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exelon","generic_name":"rivastigmine","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Acetylcholinesterase, Cholinesterase, Acetylcholine receptor subunit epsilon","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"ropinirole","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Requip","generic_name":"ropinirole","company_name":"GSK","drug_phase":"marketed","molecular_target":"D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"cogentin","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cogentin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"northera","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Northera","company_name":"The Cooper Health System","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Adrenergic receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"trihexyphenidyl","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"talipexole","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Domin","generic_name":"TALIPEXOLE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"requip","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Requip","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"procyclidine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kemadrine","generic_name":"PROCYCLIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"biperiden","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Akineton","generic_name":"BIPERIDEN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"istradefylline","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nourianz","generic_name":"ISTRADEFYLLINE","company_name":"Kyowa Kirin","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"CYP3A4 Substrates","quality_score":70,"revenue":null,"mechanism":"Nourianz works by blocking the adenosine receptor A2a, which helps to increase dopamine levels in the brain."},{"drug_id":"amantadine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gocovri","generic_name":"AMANTADINE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"benzatropine","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cogentin","generic_name":"benzatropine","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"safinamide","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xadago","generic_name":"SAFINAMIDE","company_name":"Mdd Us","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] B","drug_class":"Monoamine Oxidase Type B Inhibitor","quality_score":65,"revenue":null,"mechanism":"Xadago works by blocking the enzyme amine oxidase [flavin-containing] B, which breaks down dopamine in the brain."},{"drug_id":"rasagiline","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azilect","generic_name":"RASAGILINE","company_name":"Teva","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6","drug_class":"Monoamine Oxidase Inhibitor","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"gocovri","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GOCOVRI","company_name":"Oregon Health and Science University","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ongentys","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ongentys","company_name":"Bial - Portela C S.A.","drug_phase":"marketed","molecular_target":"Catechol O-methyltransferase, Catechol O-methyltransferase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amantadin","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amantadin","company_name":"Centre Hospitalier Universitaire de Nice","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zelapar","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zelapar","company_name":"Baylor College of Medicine","drug_phase":"marketed","molecular_target":"Alpha-synuclein, Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"foslevodopa","indication_name":"Motor fluctuations in advanced Parkinson’s disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FOSLEVODOPA","company_name":"AbbVie GK","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":"Foslevodopa works by increasing the levels of levodopa in the brain, which helps to alleviate symptoms of Parkinson's disease."},{"drug_id":"bromocriptin","indication_name":"Parkinson's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bromocriptin","company_name":"University Hospital, Bonn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pramipexole","indication_name":"Parkinson's Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PRAMIPEXOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":11,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":38,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05796037","title":"An Observational Study of Patients Living With Chronic Neurological Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500000,"lead_sponsor_name":"Target PharmaSolutions, Inc.","has_results":false},{"nct_id":"NCT07205978","title":"Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Institut Investigacio Sanitaria Pere Virgili","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT03285230","title":"The French E3N Prospective Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT04701177","title":"Digitally-enhanced, Decentralized, Multi-omics Observational Cohort","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Greece 2021 Committee","has_results":false},{"nct_id":"NCT01399411","title":"Agricultural Health Study Follow-up","phase":"","overall_status":"COMPLETED","enrollment_count":89656,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT06209515","title":"Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61292,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT04888364","title":"French Parkinson's Disease Cohort - NS-PARK","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT04994015","title":"Parkinson's Foundation PD GENEration Genetic Registry","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Parkinson's Foundation","has_results":false},{"nct_id":"NCT03866603","title":"Rostock International Parkinson's Disease Study (ROPAD)","phase":"","overall_status":"COMPLETED","enrollment_count":20112,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT04986020","title":"Identifying New Biomarkers of Parkinson's From Routine Brain Imaging","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"University of Plymouth","has_results":false},{"nct_id":"NCT03945968","title":"The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Russian Federation of Anesthesiologists and Reanimatologists","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT06609681","title":"Parkinson Disease: A Model of National Digital Interventions to Prevent or Slow a Rise of Non-Communicable","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Roongrooj Bhidayasiri","has_results":false},{"nct_id":"NCT04114994","title":"Longitudinal Cognitive Assessment by BoCA","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Alzheimer's Light LLC","has_results":false},{"nct_id":"NCT04375280","title":"Evaluation of Impaired Mobility in Chronic Illness Constitution of a Cohort","phase":"NA","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT06151002","title":"PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's","phase":"","overall_status":"RECRUITING","enrollment_count":4800,"lead_sponsor_name":"University College London Hospitals","has_results":false},{"nct_id":"NCT05413291","title":"Natural History Protocol for Movement Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT04214509","title":"LIPAD - LRRK2 International Parkinson's Disease Study","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"University of Luebeck","has_results":false},{"nct_id":"NCT00367900","title":"Parkinson's Genes and Environment Study","phase":"","overall_status":"COMPLETED","enrollment_count":3100,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT03508960","title":"Chinese EOPD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT04957420","title":"The Practical Effect of Neupro","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT03887663","title":"Chinese PD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT03523052","title":"Chinese PD-SNCA Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT03924414","title":"Trial of Parkinson's And Zoledronic Acid","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2650,"lead_sponsor_name":"California Pacific Medical Center Research Institute","has_results":false},{"nct_id":"NCT02881099","title":"Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)","phase":"","overall_status":"COMPLETED","enrollment_count":2614,"lead_sponsor_name":"South Glasgow University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT07439926","title":"Description of the Reasons for Hospitalization of Patients With Parkinson's Disease Following Admission Through the Adult Emergency Department","phase":"","overall_status":"COMPLETED","enrollment_count":2580,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05209698","title":"Self-Management Behaviors of Arabs and Jews With Parkinson's Disease and Their Associations With Health Outcomes","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"University of Haifa","has_results":false},{"nct_id":"NCT00136721","title":"Parkin Mutations and Their Functional Consequences","phase":"","overall_status":"COMPLETED","enrollment_count":2500,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT03837067","title":"Use and Misuse of Domperidone in Parkinson's Disease in France - Dump Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":2300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06092125","title":"Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT03536104","title":"Identification of Risk Factors Parkinson's Disease by Convergence Strategy","phase":"","overall_status":"COMPLETED","enrollment_count":2220,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT03279445","title":"Parkinson's Disease in African American and Caucasian Patients","phase":"","overall_status":"COMPLETED","enrollment_count":2033,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT03233646","title":"Retinal Imaging in Neurodegenerative Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06719583","title":"Black and African Americans Connections to Parkinson's Disease (BLAAC PD)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Michael J. Fox Foundation for Parkinson's Research","has_results":false},{"nct_id":"NCT06949865","title":"AI-Enhanced Optimization of Acute Levodopa Challenge Test","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT04057794","title":"PDGeneration: Mapping the Future of Parkinson's Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1982,"lead_sponsor_name":"Parkinson's Foundation","has_results":false},{"nct_id":"NCT00044590","title":"Parkinson's Diseases Susceptibility Genes and Pesticides","phase":"","overall_status":"COMPLETED","enrollment_count":1870,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT05266872","title":"Earlier Diagnosis and Better Treatment Mission Related to the Cohort Programme","phase":"","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Luxembourg Institute of Health","has_results":false},{"nct_id":"NCT07314190","title":"Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1799,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT06224725","title":"Acrylamide and Health Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":1700,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04653584","title":"Use and Misuse of Domperidone in Parkinson's Disease in France - Observational","phase":"","overall_status":"TERMINATED","enrollment_count":1579,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04023201","title":"Nocturnal Symptoms and Quality of Life in Patients With Parkinson's Disease in Shanghai","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT03508986","title":"Chinese FPD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT04576676","title":"Environmental Epidemiology of Essential Tremor","phase":"","overall_status":"COMPLETED","enrollment_count":1497,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03792204","title":"the Prevalence of \"Wearing-off\" in Patients With Parkinson's Disease in Shanghai","phase":"","overall_status":"COMPLETED","enrollment_count":1480,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06479083","title":"Interdisciplinary + Intersectoral Telemedicine Evaluation, Coordination + Treatment in RhineMain+ Parkinson's Network","phase":"NA","overall_status":"RECRUITING","enrollment_count":1354,"lead_sponsor_name":"Johannes Gutenberg University Mainz","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}